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The evidence on the cost and cost-effectiveness of global training programs is sparse. This manager’s guide to cost-
effectiveness analysis (CEA) is for professionals who want to recognize and support high quality CEA. It focuses on
CEA of training in the context of program implementation or rapid program expansion. Cost analysis provides cost
per output and CEA provides cost per outcome. The distinction between these two analyses is essential for making
good decisions about value. A hypothetical example of a cost analysis compares the cost per trainee of a
computer-based anti-retroviral therapy (ART) training to a more intensive ART training. In a CEA of the same
example, cost per trainee who met ART clinical performance standards is compared. The cost analysis is misleading
when the effectiveness differs across trainings. Two additional hypothetical examples progress from simple to more
complex costs and from a narrow to a broader scope: 1) CEA of the cost per ART patient with 95% adherence that
compares the performance of doctors to counselors who attend additional training, and 2) CEA of the cost per
infant HIV infection averted for a Prevention of Mother to Child Transmission program that compares the current
program to one with additional training. To create an evidence base on CEA of training, more well-designed
analyses and data on the cost of training are needed. Analysts should understand more about how capacity is built,
how quality is improved within a health facility, and the costs associated with them. Considering the life of an
investment in training, evaluations are needed on how many trainees apply the skills taught, how long trainees
continue to apply them, and how long the content of the training conforms to national or international guidelines.
Better data on effectiveness of training is also needed. It is feasible to measure effectiveness by clinical performance
standards, or intermediate outcomes and coverage. Intermediate outcomes and coverage can also be combined
with published estimates on health outcomes.
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The global response to the HIV epidemic is one of the lar-
gest public expenditures to fight a single disease in history
[1,2]. This scaled-up response to the HIV epidemic re-
quired large numbers of doctors, allied health profes-
sionals, and administrative support staff with new, specific
HIV clinical and management skills. Recognizing this
need, governments, non-governmental organizations, and
other international organizations invested heavily in HIV
training of health care providers in Africa, Asia, and Latin
America. For example, between 2004–2009, as part of the
President’s Emergency Plan for AIDS Relief [3] 213,200* Correspondence: gomalley@uw.edu
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reproduction in any medium, provided the orhealth care providers were trained in Prevention of Mater-
nal to Child Transmission (PMTCT) and 304,700 were
trained in anti-retroviral therapy (ART).
Global programs for HIV are now moving from emer-
gency response to address sustainability, task-shifting, and
integrating HIV care and treatment into primary health
care and chronic disease management. This transition will
likely involve continuing major investments in training
[4,5], and program managers will be looking for good
value for these investments. Cost-effectiveness analysis
(CEA) is a powerful method to identify value, but many of
the well-established methods for conducting these ana-
lyses for clinical trials, demonstration projects, and other
research have not been applied to scaling-up interventions
and the training programs that support it. A notable ex-
ception is the WHO Choice Project that estimated thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to achieving the Millennium Development Goals [6].
Program managers will find evidence is sparse on the
cost-effectiveness of global training programs in general
[7] and HIV training programs in particular [8]. School-
ing and training are investments, known as human capital
[9]. CEA of global training to date have focused on how
and who to train, as well as training as a component of a
larger intervention. Analyses of how to train have
addressed the most effective means of training a specific
group of health care providers [10-13]. Analyses of who to
train have addressed task-shifting or task-sharing in which
training was extended to a group of health care providers
who assumed new responsibilities for specific services
[14-18]. Finally, some analyses have estimated the cost-
effectiveness of interventions that included training for the
health care providers who implemented them [19-21].
To create an evidence base on the CEA of training, pro-
gram managers will need to deploy analytic resources
wisely. This article has been written as a guide for pro-
gram managers who may not be economists, but want to
recognize and support high quality CEA of training. It fo-
cuses on the approaches and challenges associated with
conducting CEA of training in the context of program
implementation or rapid expansion of programs. For a
general consumer’s guide, please see the Panel on Cost-
Effectiveness in Health and Medicine’s book [22] or arti-
cles [23-25]. The National Library of Medicine offers a
free, less technical resource in its online course “Health
Economics Information Resources: A Self-Study Course”,
which focuses on identifying CEA studies, and appraising
their quality [26]. For professionals who plan to conduct
CEA, Drummond et al. [27] is a well-respected introduc-
tion. In addition, UNAIDS [28] created guidelines with in-
structions for conducting cost analyses of HIV prevention
strategies that can be extended to other HIV programs
such as training. These excellent resources, however, pre-
date the scale-up of HIV treatment and care and are ori-
ented to trials, demonstration projects, and other research.
This manager’s guide begins with definitions of cost
analysis and CEA. Understanding the distinction between
these two analyses is essential for making good decisions
about value. Then, three hypothetical examples of CEA of
training programs are presented: 1) cost per trainee who
met ART clinical performance standards; 2) cost per pa-
tient with 95% ART adherence; and 3) cost per HIV infec-
tion averted. Each example provides insights on both
measures of cost and effectiveness that would contribute
to a CEA in the context of program scale-up.
Cost analysis
A cost analysis estimates the cost per unit of output,
where costs are the value of all inputs that a program
uses. The inputs typically consist of the time of trainersand trainees, supplies, teaching materials, and possibly
equipment, facility space and transportation. Consider a
simple hypothetical example in which a program manager
is planning to scale-up ART services at a clinic. S/he com-
pares two trainings to upgrade the skills of 25 clinical staff
in monitoring patients on ART. One is a computer-based
training followed by a three-day practical workshop. The
second is an intensive, two-week workshop followed by
two on-site trainings. Table 1 presents the cost for the two
programs in three categories: 1) training program budget,
2) training venue contract, and 3) ministry of health con-
tribution. For the personnel costs in the training program
budget, the remuneration rate, which includes salary and
fringe benefits, is multiplied by the number of units (e.g.,
hours, days, months). The subtotal, which is the sum of
the cost for each person, is $7,350 for the computer-based
training, and $12,250 for the intensive training.
A cost analysis can differ from a training program
budget for at least two reasons: 1) multiple partners con-
tribute to the training, and 2) some contributions are
“in-kind.” Training programs are often funded through a
combination of contributions by donors, the ministry of
health, and the trainees. In Table 1, the cost also includes
a training venue contract funded by a donor, and the min-
istry of health’s contributions. Each partner has a “perspec-
tive” and a cost analysis conducted from the perspective of
a single partner would focus only on that partner’s budget.
A cost analysis conducted from the societal perspective in-
cludes the contributions of all the partners as well as
trainees and patients. In Table 1, the total societal cost is
$12,025 for the computer-based training, and $20,000 for
the intensive training.
Some professional guidelines [22,23], recommend that
analysts report the cost analysis from societal perspective
as a reference case so that costs are comparable across
analyses. However, cost analyses could be reported from
additional perspectives as appropriate. Program managers
should expect analysts to identify the perspective of the
analysis and acknowledge that some costs may not be in-
cluded whenever the cost analysis is not conducted from
the societal perspective.
Partners may contribute in-kind as well as with pro-
gram budgets. In the example in Table 1, the ministry of
health contributes the trainees’ time, which should be
included in a cost analysis from a societal perspective
even if their participation did not require an extra pay-
ment to the trainees. The trainees would have engaged
in productive work had they not attended the training,
which is the opportunity cost of trainees’ time. The op-
portunity cost is the value of the most beneficial alterna-
tive feasible use of the resources. Please see the Glossary
in Table 2 for definitions of economic terms used in this
manager’s guide. This opportunity cost of the trainee’s
time is valued at the trainees’ remuneration rate, which




and two on-site trainings
Cost per unit Units Cost* Units Cost*
Training program budget
Curriculum designer $2,500/month 2 $5,000 2 $5,000
Subject matter experts $200/hour 9 $1,800 5 $1,000
Trainer $100/day 3 $300 10 $1,000
Materials: participant manuals $10/person 25 $250 25 $250
On-site training $1,000/site 0 5 $5,000
Subtotal training program $7,350 $12,250
Training venue contract
Rental $100/day 3 $300 10 $1,000
Meals and tea break $5/day 75 $375 250 $1,250
Subtotal training venue $675 $2,250
Ministry of health contribution
Trainees’ time computer-based course $20/day 125 $2,500
Trainees’ time workshop $20/day 75 $1,500 250 $5,000
Trainees’ time on-site training $20/day 0 25 $500
Subtotal ministry of health $4,000 $5,500
Total societal cost $12,025 $20,000
Cost analysis
Number of trainees 25 25
Cost per trainee 12025/25= $481 20,000/25= $800
*To calculate each cost, multiply the cost per unit by the number of units. The subtotal is the sum of all the costs in the category.
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average salary rate for each trainees’ profession, gender
and age group is used in the calculation; detailed data
on each person’s salary are not necessary.
For the cost analysis, the total societal cost is divided
by the number of outputs. For training activities, the
output produced is typically the number of people
trained. In this example, the cost per trainee is $481 for
the computer-based training program, and $800 for the
intensive training. Program managers should, however,
be wary of cost per unit of output. In routine reporting,
someone who attended a one-hour lecture might be
counted the same way as someone who completed a
one-year fellowship, i.e., as a “person trained”. Be-
cause of the large difference in resources required
and presumably the skills enhancement achieved, an
analysis that simply compared the cost per trainee
would be misleading. A CEA that measures the cost
per outcome can address differences in effectiveness
across trainings.
Cost-effectiveness analysis (CEA)
As applied to health and medicine, a CEA estimates the
cost per unit of health outcome such as an HIVinfection averted or a year of life gained. The fewer dol-
lars required to achieve an outcome, the more cost-
effective the intervention is considered to be. For ex-
ample, an adult male circumcision program that costs
$500 per HIV infection averted is more cost-effective
than a voluntary counseling and testing program that
costs $5,000 per HIV infection averted.
The scope of a CEA is determined by the denominator;
only programs with a common denominator can be com-
pared. For CEA with the broadest scope, the denominator
is units of life measured by a combination of mortality and
morbidity. Two widely used measures are: QALYs and
DALYs. Both measures account for years of life gained
from reduced mortality, and improved quality of life dur-
ing years of reduced morbidity. Both measures also have
weights for years of reduced morbidity ranging from zero
to one, but the similarities end there. For example, QALYs
measure quality of life where death is zero and full health
is one, whereas DALYs measure disability where zero is
full health and one is death. The measures also differ in
objectives, how units of life are characterized, and the
methods for calculating the weights associated with each
characteristic. Gold et al. provide an excellent comparison
between the two measures [29].
Table 2 Glossary of cost and cost-effectiveness terms
Annuitization Method of allocating the cost of an investment (i.e. a capital cost) over the time period when it is used. When
discounting is ignored, annuitization is calculated as the cost of investment divided by the number of years of
life of investment.
Capital Cost It is an investment in an asset such as buildings, land, vehicles or equipment that is used over more than one year.
The investment is generally a single purchase that may precede the project, so that its cost is not always included in
the project budget. The asset has an opportunity cost and its annual cost call be allocated over time.
Cost analysis Estimate of the cost per unit of output, where outputs are the activities or services, such as health care providers
trained or patients treated.
Cost-effectiveness analysis
(CEA)
Analysis of the cost per unit of outcome. The outcome serves as the denominator and must be the same for
interventions and programs that are compared. CEA of health and medicine, are generally conducted with
health outcomes.
Cost effectiveness ratio The ratio of cost to outcomes. When two programs are not explicitly compared, the ratio represents the cost-
effectiveness of the program of interest relative to doing nothing.
Disability Adjusted Life Years
(DALY)
A measure of the burden of disease of a population in terms of years lost due to ill-health or death. Years of life
are weighted from zero to one where zero represents full health and one represents death. Health is
characterized by disease categories, and the weights associated with diseases are determined by expert opinion.
Dominance An intervention or program with a lower cost and better outcomes than the alternative.
Incremental Cost Effectiveness
Ratio (ICER)
The ratio of the difference in cost between two programs and the difference in their effectiveness. The ratio
represents the additional cost associated with each additional unit of outcome.
Opportunity Cost The value of the most beneficial alternative feasible use of resources for an activity. For goods and services that are
purchased in a competitive market, the opportunity cost is simply the price. Goods and services that are not
purchased such as volunteer time should be valued at the cost of purchasing them. Similarly, for goods or services
that are subsidized or taxed, they should also be valued at cost to purchase them without the subsidy or tax.
Perspective The point of view from which costs are calculated. Six potential perspectives for a cost analysis of training are:
1) Program perspective might simply be the program budget, 2) Donor perspective would include the budgets
of all programs that contribute to an output or outcome, 3) Provider perspective represents the costs of the
health care system, including ministry of health, hospitals and clinics, 4) Trainee perspective might be earnings
from private practice foregone while attending training, as well as tuition, 5) Patient perspective includes the
out-of-pocket expenditures for health care and the time devoted to care for themselves or family members. 6)
Societal perspective represents all costs regardless of who bears them including: programs, donors, providers,
trainees, and providers.
Quality Adjusted Life Year
(QALY)
A measure of health of a sample in terms of quality of life years of life lost due to ill-health or death. Years of
life are weighted from zero to one where zero represents death or an equivalent state, and one represents full.
Health is characterized by health states such as the ability to walk a mile and the weights associated with health
states are reported by patients or the community through various research methods.
Remuneration The total amount of resources a consultant or employee receives including salary and fringe benefits.
Sensitivity analysis Calculation of alternative cost-effectiveness results when there is uncertainty about one or more parameters that
measure costs or effects. Sensitivity analysis is generally incorporated in CEA that are deterministic, meaning the
result is a point estimate. It helps to identify the extent to which uncertainty about a parameter would
substantially affect the estimate.
O’Malley et al. Human Resources for Health 2013, 11:20 Page 4 of 9
http://www.human-resources-health.com/content/11/1/20As a practical matter, program managers rarely have
time or funding to support a CEA that measures the
specific contribution of training to health outcomes. For-
tunately, an intermediate measure, such as the number
of health care providers that perform a task competently,
or an intermediate outcome such as the number of pa-
tients who adhere to treatment may be an appropriate
denominator for some analyses. It may also be possible
to collect original data on an intermediate measure and
use published estimates to calculate the health out-
comes. These three options are presented in three hypo-
thetical examples below.
Intermediate measure
Continue with the hypothetical example above in which
the computer-based ART training and intensive ARTtraining are compared. The program manager monitors
a comprehensive set of costs that extend beyond the
training events to include the cost of transfer of learning.
As shown in Table 3, the total societal cost of the
computer-based training is $12,025 and of the intensive
training is $20,000 as in Table 1. The cost analysis in
Table 3 also includes the time senior staff spent with
graduates after the training to support them to apply
their new skills, such as ad hoc sessions in the context
of actual patient visits. This cost of the supervisors’ time
in providing this additional support is $8,000 among
graduates of the computer-based training versus $2,000
among graduates of the intensive training. The total cost
of the training and transfer of learning is $20,025 for the
computer-based training and $22,000 for the intensive
training.
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clinical performance to compare the effects of the train-
ings. A graduate who performs 80% of the tasks correctly
meets the standard. In spite of post-training support, only
15 graduates of the computer-based training meet the
standard, whereas 22 graduates of the intensive training
do. Each training is compared to no training, i.e., doing
nothing, so the cost-effectiveness ratio is simply the total
societal cost divided by the number of trainees who meet
the standard. As shown in Table 3, the cost per success-
fully trained graduate of the computer-based training is
$1,335 versus $1,000 for the intensive training.
The key to this result is collecting cost data on all the
activities associated with transfer of learning and meas-
uring effectiveness in terms of clinical performance. If
success was measured simply by the number of trainees
as in Table 1, the lower cost per graduate might displace
competence as the standard for selecting a training.
Intermediate health outcomes
Intermediate health outcomes are used in a CEA with a
somewhat broader scope. Consider an agency that is
committed to providing ART to HIV-infected adults and
children. Since the health benefits of ART are well-
documented [30-33], a program manager might want to
focus on extending coverage and improving adherence.
The program manager’s question in this instance is
“How can I allocate my budget to provide high qualityTable 3 CEA with an intermediate outcome: cost per

























Cost per trainee who
meet ART clinical
performance standard
$20,025/12 = $1335 $22,000/23 = $1000
*Transfer of learning includes both the training events and follow-up support.
**The ART clinical performance standard is to perform 80% of the task correctly.
According to this measure, the computer-based training was less effective.care to the most patients?” This broader scope supports
comparison of training programs to other activities that
may affect coverage and adherence, such as pharmacy
logistics, continuous quality improvement, or leadership
initiatives.
In this hypothetical example (Table 4), a clinic is pro-
viding ART in an impoverished urban setting where
many patients have substance abuse problems, or other
challenges to adherence. While good adherence is not a
health outcome, studies showed that the correlation be-
tween good adherence and viral suppression is high
[34-38]. The program manager adopts an intermediate
outcome; the number of patients maintaining 95% ad-
herence. Some experts argue that setting a high standard
for adherence is discouraging to patients, and alternative
levels such as 80% or simply mean adherence among pa-
tients could also be used in an analysis [35].
Prior to training, relatively highly-paid doctors spend
much of their time screening patients at risk for poor
adherence, counseling them, and referring them for add-
itional support. As shown in the Pre-training column of
Table 4, ART services cost $150,000 and served 400 pa-
tients each year. Adherence is 95% among 360 patients
(90%) at a cost of $417 per patient with 95% adherence.
The program manager sees an opportunity to increase
coverage through task-shifting or task-sharing and funded
training for counselors to assume responsibility for the
screening, counseling, and referral activities. In this ex-
ample, as the measure of effectiveness shifts from trainees
to patients, the benefits of an investment in training last
several years when trained staff continue to apply their
new skills. The annual measures of patient outcomes are
compared to the annual cost of the investment in training.
Distributing the cost of an investment over time is called
“annuitization.” Just as the use of a $40,000 automobile
can extend for 10 years at a cost of $4,000 per year, the
total cost of training, say $20,000 in this example, that ex-
tends for four years is $5,000 per year (for simplicity,
discounting is ignored in these examples.) The annual cost
depends on how many trainees apply the skills learned,
how long they apply them, and how long the new skills re-
main the standard of care. For example, Hiner et al.
reported that 65% of trainees provided voluntary counsel-
ing and testing in the Caribbean three years after training
on these services [39]. Namagembe et al. reported that im-
proved clinical practice persisted for at least one year after
a malaria case management training program [40]. Re-
search in the United States showed that 50% of practice
guidelines were outdated in 5.8 years [41].
As shown in the Post-training column, the annual
training cost is $5,000. There are other changes in cost
after the training. Personnel costs decrease from $50,000
to $30,000 as doctors with high salaries are replaced by
counselors. The trained counselors move patients
Table 4 CEA with an intermediate health outcome: cost





Total program cost $150,000 $140,000
Cost of training (annuitized)* $0 $5,000
Total cost $150,000 145,000
Cost-effectiveness analysis
Number of patients 400 440
Percentage of patients with 95%
ART adherence
90% 85%




*The annual cost of a $20,000 training with a four-year life of investment
is $5,000.
**No cost-effectiveness ratio is necessary, because a program with lower cost
and higher effectiveness dominates the alternative.
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process more quickly, which increases the number of pa-
tients on ART from 400 to 440. Some of the savings in
personnel costs are offset by the cost of medications for
40 additional patients. Total program cost decreases from
$150,000 to $140,000, which would not be the case if the
total cost of training were allocated to the first year.
The quality of the new screening, counseling, and re-
ferral activities is, however, lower than before the train-
ing; the counselors are less effective than doctors.
Adherence is 95% for 374 of 440 patients (85%). Never-
theless, the expanded coverage means that more patients
achieve 95% adherence post training than before. The
training dominates the alternative, because the total cost
is lower and number of patients with 95% adherence is
higher post training than before. The key to this result is
tracking service volume to show the training is more cost-
effective than if the CEA focused only on adherence.
Health outcomes
The hypothetical example in Table 5 combines data on
coverage with published estimates of the health out-
comes associated with PMTCT. Before an intervention
is scaled-up in HIV care, there is generally extensive re-
search on its effectiveness. It is neither feasible nor ne-
cessary for each training to replicate the earlier research.
It is sometimes possible to apply the results of earlier
research to estimate the effects of training on health out-
comes. The CEA Registry is a good resource for identify-
ing previous research on cost-effectiveness [42].
Even the best research, however, may not provide a
single estimate of costs or effects. Results from a singlestudy are reported as a mean and confidence interval,
and results may not be identical across multiple studies.
When there is uncertainty about parameter estimates,
analysts conduct a sensitivity analysis with a base case
and alternative estimates that show a range of cost-
effectiveness ratios. Uncertainty may exist for a variety
of reasons and this example demonstrates a sensitivity
analysis for estimates of health outcomes.
Considering PMTCT, HIV is transmitted during ante-
natal, delivery, and breastfeeding periods, but it is not
possible to identify precisely the transmission associated
with each period with available HIV testing methods.
Research in the 1990’s showed that, in the absence of
treatment, HIV transmission in the antenatal or intra-
partum period ranged from 19% to 30% and transmis-
sion during breastfeeding ranged from 10% to 16% [43].
More precise estimates may never exist, because the
earlier studies proved that treatments were effective
and it would now be unethical to withhold treatment.
Consequently, a CEA would present a sensitivity analysis
of the effect of a PMTCT training on HIV infections
averted.
Begin with the cost analysis of the PMTCT program
in a district hospital that cost $100,000 per year. The pro-
gram manager wants to know if money spent on coun-
selors’ training is well spent. If so, s/he will seek funding
to extend this training to other PMTCT sites. Before the
training, costs are apportioned across personnel, medica-
tions and capital categories as shown in Table 5. Personnel
costs are calculated in two categories: 1) clinic staff, in-
cluding counselors, and 2) supervisory staff. For clinic
staff, the number of full-time equivalent (FTE) staff pro-
viding counseling, HIV testing, and ART screening and
treatment is multiplied by their remuneration rate per
FTE for a total of $65,000. For supervisory staff, the por-
tion of their time spent supporting PMTCT is multiplied
by their remuneration rate for a total of $15,000. For sup-
plies, $15,000 is spent on HIV test kits, ARV drugs, and
other supplies. Capital costs are calculated for three cat-
egories, each annuitized to an annual cost: 1) transporta-
tion is $3,000, 2) equipment such as refrigerators,
computers and furniture is $500, and 3) building is $1,500.
The ministry of health provides the hospital building used
for PMTCT free-of-charge. Nevertheless, absent PMTCT,
the space could be used for other worthwhile activities. Its
opportunity cost is approximated by the annual rent for
equivalent space if procured on the market.
For the pre-training effectiveness, the program serves
1,000 women and infant pairs per year who complete
the ARV regimen. The number of infant HIV infections
averted each year is estimated by multiplying the num-
ber of women and infant pairs by the published ante-
natal and intrapartum transmission rates [43] and
published estimate of 63% efficacy for the PMTCT








Supervisory staff $15,000 $12,000
Total remuneration $80,000 $84,000
Supplies, including HIV







Total Capital $5,000 $10,000
Total program cost $100,000 $112,000
Estimate of effectiveness






Base case 25% 25%
Lower bound 19% 19%
Upper bound 30% 30%
Effectiveness of regimen




Base case (1000*.25*.63) =158 (1000*.25*.63) =189
Lower bound 120 144
Upper bound 189 227
Cost-effectiveness analysis
Incremental cost ($112,000-$100,000) = $12,000
Incremental HIV
infection averted
Base case (189–158) = 31
Lower bound (144–120) = 24






*The effect of the training on MTCT is uncertain because there is a range of
estimates for vertical HIV transmission before and during birth. The midpoint
of the range is used to estimate effectiveness for the base case, and a
sensitivity analysis is conducted with the lower and upper bounds. The base
case and range are also reported for the number of HIV infections averted
and ICER.
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and intrapartum transmission rates, the base case uses
the midpoint of the range of estimates (25%), and the
sensitivity analysis uses the lower (19%) and upper (30%)
bounds. As shown in Table 5, the base case estimate of
the number of HIV infections averted is 158 with a
range from 120 to 189.
Post-training, the cost changes in important ways. Be-
cause the counseling protocol requires longer counseling
sessions and smaller group sizes, the personnel cost of
clinical staff, including counselors, increases from
$65,000 to $72,000 annually. The training includes rou-
tine record keeping, however, and allows senior nurses
to take on supervisory functions formerly left to more
highly paid supervisors. The result is a reduction in
personnel costs of supervisors from $15,000 to $12,000
per year. The cost of supplies increases from $15,000 to
$17,000, because more women and infants complete the
PMTCT sequence and consequently use test kits and
ARV drugs. The training program cost $20,000 and it
is estimated to have four years of benefit before skills
degrade or staff members leave, with an annual cost of
$5,000 per year.
For the post-training effectiveness, the number of
women and infant pairs who complete the PMTCT regi-
men increases to 1,200. The base case estimate of the
number of HIV infections averted is 189 with a range
from 144 to 227. Both cost and HIV infections averted
increased. The incremental cost-effectiveness ratio is the
increase in total cost ($112,000 – $100,000) divided by
the increase in infections averted (189 – 158), which is
$283 per HIV infection averted with a range from $215
to $340.Conclusions
The cost data included in a cost analysis depend on its
perspective. Some professional guidelines recommend
that published cost analysis report the societal perspec-
tive, which include the cost of all partners, as well as
trainees and patients. Cost analyses can, however, be
misleading when the effectiveness of the trainings differ.
A CEA can guide program managers to make the best
investments in training. The three hypothetical examples
progressed from simple to complex costs and a narrow
to broader scope to highlight key concepts about meas-
uring the cost and effects of training in the context of
program implementation or rapid expansion.
To create an evidence base on CEA of training, the ex-
amples in this manager’s guide demonstrate the need
for more well-designed analyses and data on the cost of
training. Analysts should understand more about how
capacity is built, how quality is improved within a health
facility, and the costs associated with them. The analyses
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building and quality improvement change in response
to training. Considering the life of an investment in
training, analysts should focus on how many trainees
apply skills taught during the training, how long
trainees continue to apply them, and how long the
content of the training conforms to national or inter-
national guidelines.
The examples also demonstrate the need for better
data on effectiveness of training programs. It is feasible
to conduct CEA of training in which effectiveness is
measured by clinical performance standards, or inter-
mediate outcomes and coverage. Intermediate outcomes
and coverage can also be combined with published
estimates on health outcomes to estimate the effect of
training on health outcomes. Program managers are
encouraged to maintain a focus on these effectiveness
measures rather than outputs and to invest in trainings
with the lowest cost per improvement in them.
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